|
[1]
|
Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia[J]. Clin Infect Dis, 2004, 39:165-169. doi: 10.1086/421497 |
|
[2]
|
Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia:a systematic review[J]. J Infect, 2011, 63:187-199. doi: 10.1016/j.jinf.2011.06.009 |
|
[3]
|
Meijvis S, Hardeman H, Remmelts H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia:a randomized, double-blind, placebo-controlled trial[J]. Lancet, 2011, 377:2023-2030. doi: 10.1016/S0140-6736(11)60607-7 |
|
[4]
|
Monton C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia:a pilot study[J]. Eur Respir J, 1999, 14:218-220. doi: 10.1034/j.1399-3003.1999.14a37.x |
|
[5]
|
Rosewicz S, MvDonald AR, Maddux BA, et al. Mechanism of glucocorticoid receptor down-regulation by glucocorticoids[J]. J Biol Chem, 1998, 263:2581-2584. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=d5087fbae85b91a432c8feadba552e1f |
|
[6]
|
Artigas A, Bernard GR, Carlet J, et al. The American-European Consensus Conference on ARDS, part 2:Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 1998, 157:1332-1347. doi: 10.1164/ajrccm.157.4.ats2-98 |
|
[7]
|
Ware LB, Matthay MA. The acute respiratory distress syndrome[J]. N Engl J Med, 2000, 342:1334-1349. doi: 10.1056/NEJM200005043421806 |
|
[8]
|
Jordi A, Ignasi B, Pere T, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia[J]. Chest, 2004, 125:1335-1342. doi: 10.1378/chest.125.4.1335 |
|
[9]
|
Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects:antagonism of transcription factor activity by glucocorticoid receptor[J]. J Leukoc Biol, 2002, 71:9-15. http://www.ncbi.nlm.nih.gov/pubmed/11781376 |
|
[10]
|
Franchimont D, Martens H, Hagelstein MT, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increaseases, the sensitivity of human monocytes to dexamethasone:potential regulation of the glucocorticoid receptor[J]. J Clin Endocrinol Metab, 1999, 84:2834-2839. |
|
[11]
|
Wagner Jr HN, Bennett Jr IL, Lasagna L, et al. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with ppenicillin[J]. Bull Jhons Hopkins Hosp, 1956, 98:197-215. http://www.cabdirect.org/abstracts/19562703405.html;jsessionid=92A015867537A0E6C96B9CA48A5F5502 |
|
[12]
|
Kaplan JE, Benson C, Holmes KH, et al; Centers for Disease Control and Prevention(CDC); National Institutes of Health; HIV Medicine Association of the Infectious Disease Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of Institutes of Health, and the HIV Medicine Association of the Infectious Disease Society of America[J]. MMWR Recomm Rep, 2009, 58(RR-4):1-207. |
|
[13]
|
ANZIC Influenza Investigators, Webb SA, Pettila V, Seppelt I, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand[J]. N Engl J Med, 2009, 361:1925-1834. doi: 10.1056/NEJMoa0908481 |
|
[14]
|
Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada[J]. JAMA, 2009, 302:1872-1879. doi: 10.1001/jama.2009.1496 |
|
[15]
|
Quispe-Laime AM, Bracco JD, Barberio PA, et al. H1N1 influenza A virus-associated acute lung injury:response to combination oseltamivir and prolonged corticosteroid treatment[J]. Intensive Care Med, 2010, 36:33-41. doi: 10.1007/s00134-009-1727-6 |
|
[16]
|
Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection[J]. Intensive Care Med, 2011, 37:272-283. doi: 10.1007/s00134-010-2078-z |
|
[17]
|
Brun-Buisson C, Richard JC, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2011, 183:1200-1206. doi: 10.1164/rccm.201101-0135OC |
|
[18]
|
Hui DS, Lee N, Chan PK. Clinical management of pandemic 2009 influenza A (H1N1) infection[J]. Chest, 2010, 137:916-925. doi: 10.1378/chest.09-2344 |
|
[19]
|
Zhang Y, Li J, Zhan Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome[J]. Infect Immun, 2004, 72:4410-4415. doi: 10.1128/IAI.72.8.4410-4415.2004 |
|
[20]
|
Sung JJY, Wu A, Joynt GM, et al. Severe acute respiratory syndrome:report of treatment and outcome after a major outbreak[J]. Thorax, 2004, 59:414-420. doi: 10.1136/thx.2003.014076 |
|
[21]
|
Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults:Meta-analysis[J]. BMJ, 2008, 336:1006-1009. doi: 10.1136/bmj.39537.939039.BE |
|
[22]
|
Tang BM, Craig JC, Eslick GD, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome:a systematic review and meta-analysis[J]. Crit Care Med, 2009, 37:1594-1603. doi: 10.1097/CCM.0b013e31819fb507 |
|
[23]
|
Meduri GU, Marik PE, Chrousos GP, et al. Steroid treatment in ARDS:a critical appraisal of the ARDS network trial and the recent literature[J]. Intensive Care Med, 2008, 34:61-69. doi: 10.1007/s00134-007-0933-3 |
|
[24]
|
Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS:results of a randomized controlled trial[J]. Chest, 2007, 131:954-963. doi: 10.1378/chest.06-2100 |
|
[25]
|
Meduri GU, Golden E, Umberger R. Prospective double-blind randomized clinical trial on the effects of low-dose hydrocortisone infusion in patients with severe sepsis[J]. Chest, 2009, 136:45S. doi: 10.1016/s0012-3692(16)48001-3 |
|
[26]
|
Sprung CL, Caralis PV, Marcial, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study[J]. N Engl J Med, 1984, 311:1137-1143. doi: 10.1056/NEJM198411013111801 |
|
[27]
|
Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock[J]. N Engl J Med, 1987, 317:653-658. doi: 10.1056/NEJM198709103171101 |
|
[28]
|
Annane D, Sebille V, Charpentier C. Effect of treatment with low doses of hydrocortisone and fludrocortisones on mortality in patients with septic shock[J]. JAMA, 2002, 288:862-871. doi: 10.1001/jama.288.7.862 |
|
[29]
|
Sprung CL, Annane D, Keh D. Hydrocortisone therapy for patients with septic shock[J]. N Engl J Med, 2008, 358:111-124. doi: 10.1056/NEJMoa071366 |
|
[30]
|
Siempos Ⅱ, Vardakas KZ, Kopterides P, et al. Adjunctive therapies for community-acquired pneumonia:a systematic review[J]. J Antimicrob Chemother, 2008, 62:661-668. doi: 10.1093/jac/dkn283 |
|
[31]
|
Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group[J]. N Engl J Med, 1999, 340:1941-1947. doi: 10.1056/NEJM199906243402502 |
|
[32]
|
van Staa TP, Leufkens HGM, Abenhaim L, et al. C. Use of oral corticosteroid and risk of fractures[J]. J Bone Miner Res, 2000, 15:993-1000. doi: 10.1359/jbmr.2000.15.6.993 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
